anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Arctium lappa L. polysaccharide (ALP) is a prominent bioactive compound renowned for its multifaceted functional properties, including anti-inflammatory, antioxidant, antifibrotic, immunomodulatory, and pro-apoptotic effects. This study evaluated the aging-delaying effect of ALP and its mechanisms using a D-galactose (D-gal)-induced aging model. After an 8-week treatment, ALP significantly ameliorated D-gal-induced inflammation and oxidative stress in the liver, kidneys, and intestines. Notably, ALP administration led to a marked reduction of the pathogenic bacterium Desulfovibrio and a substantial increase in the beneficial bacterium Muribaculum. These microbial shifts were associated with upregulated expression of intestinal tight junction proteins and intestinal mucins, leading to enhanced intestinal barrier integrity. Consequently, the leakage of enterotoxins and inflammatory mediators was effectively reduced. The findings indicate that ALP alleviates tissue inflammation and oxidative stress, while also delaying aging in mice. This effect is achieved through the regulation of intestinal ecological homeostasis and the repair of the intestinal immune barrier.
The invention belongs to the technical field of medicines, and relates to a bepotastine besilate composition and a preparation prepared thereby, and the preparation particularly relates to a bepotastine besilate tablet. The composition is prepared from bepotastine besilate, mannitol and solid-state polyethylene glycol polymer, and the partical sizes of bepotastine besilate, mannitol and solid-state polyethylene glycol polymer are all controlled at D90 of 200 micrometers to 300 micrometers. The preparation is a bepotastine besilate preparation containing the bepotastine besilate composition. In particular, the bepotastine besilate tablet is prepared from the bepotastine besilate composition and a pharmaceutically acceptable carrier. The composition has good flowability and pressing ability, and is used for preparing the bepotastine besilate tablet and other preparations which are easy to mix evenly and shape by tablet compressing, thus a finished product with uniform content and stable quality is obtained. The preparation method is easy, operation is convenient, requirements for production equipment are low, and it is easy to realize industrialization.
Hypernatremia is frequently encountered in patients admitted to the Intensive Care Unit (ICU) and associated with increased mortality and length of stay. The main mechanism is an imbalance between sodium and total body water. Consequently, this poses multiple factors to play a role in the development of hypernatremia. multifactorial. Previous studies focused on predictors in the development of hypernatremia by including amount and types of administered medication, fluid balance, laboratory results and changes in vital signs. However, data of larger populations or data on infusion rates, fluid and salt balance or renal replacement therapy is lacking. Few studies investigated the recovery of hypernatremia, which showed that correction of hypernatremia can reduce the associated mortality risk.

This study aims to provide better insight in the development and recovery of hypernatremia through the collection of detailed information on the input and output of fluids and salts in a larger group of patients than studied before.
The invention relates to a traditional Chinese medicine preparation, in particular to an orally-taken traditional Chinese medicine preparation for later-stage treatment and rehabilitation of fracture. The preparation is characterized by being prepared from, by weight, 20-30 parts of herba cynomorii, 20-30 parts of Chinese wolfberry fruits, 15-20 parts of carapax trionycis, 10-15 parts of radix morinda officinalis, 10-15 parts of shady jerusalemsage herbs, 10-15 parts of wilson passionflower herbs, 10-15 parts of Chinese ivy fruits, 15-20 parts of acanthopanax roots, 10-15 parts of bighead atractylodes rhizomes, 15-20 parts of radix paeoniae alba, 15-20 parts of rhizoma alismatis, 10-15 parts of roots or bark of euonymus nanus bieb., 5-10 parts of roots of iodes vitiginea (hance) hemsl.[erythrostaphyle vitiginea hance; iodes ovalis (nonB1.) merr.ex Groff.] and 5-10 parts of rhizomes of polygonum orientale L.. The traditional Chinese medicine preparation has the advantages that the used traditional Chinese medicine meets specifications in Pharmacopoeia of the People's Republic of China, and the medicine is safe and reliable. All medicinal materials are compatible and achieve the effects of strengthening tendons, tonifying marrow, dredging joints and the like; for later-stage rehabilitation of fracture, the preparation has the advantages of being definite in treatment effect, quick in effectiveness, high in cure rate, free of toxic or side effect and the like.
PROBLEM TO BE SOLVED: To obtain an inhibitor having acyl coenzyme A cholesterol acyl transferase activity (ACAT) inhibitory effect, thus useful for treating and preventing diseases due to the disorder of cholesterol homeostasis in vivo through its formulation in foods, medicines or cosmetics. SOLUTION: This inhibitor is a compound of formula I [R1 is an arylalkyl which may have hydroxyl group; R2 is a 2-10C acyl] which may have hydroxyl group, e.g. osmanthuside B of formula II. The compound of formula I can be easily obtained by subjecting a plant body (pref. leaves) of Ligustrum pulpurasence or Ligustrum pedoncrale to extraction with a polar solvent followed by purifying the extract through a column packed with silica gel, ODS or ion exchange resin. At least one kind of compound selected from those of formula I is put to pharmaceutical manufacturing together with arbitrary ingredients such as excipient and binder to be conventionally used in medicinal compositions to obtain the other objective medicinal composition.
Ulcerative Colitis (UC) is a disorder involving the lining of the colon. A substance called "tumor necrosis factor" (TNF) naturally occurs in the body. TNF is thought to play an important role in the development of ulcerative colitis by causing some of the damage that is seen in the colon. "Antibodies" are normally made in the body and help fight off infection. Infliximab is an antibody that is made in a scientific laboratory, using parts of both mouse and human antibodies. It has been designed to attach to TNF, making it difficult for TNF to do any damage. This study will be done at centers in North America and Europe. Each child will first have a clinic visit (screening visit) to have some tests done to make sure the child is the type of patient who should be in this study. At the 2nd visit (week 0), the child will have the first treatment with infliximab. All children in the study will receive 5 mg/kg infliximab 3 times (at weeks 0, 2 and 6) over the first 6 weeks of the study. If the child's symptoms do not improve by the 8th week, the child will receive no further infusions, but will return for safety evaluations. If the child's symptoms do improve, the child will be randomly assigned (like the flip of a coin) to either 5 mg/kg infliximab every 8 weeks through week 46 or 5 mg/kg infliximab every 12 weeks through week 42. If the child gets worse after being randomly assigned, the amount of infliximab may be increased or the infliximab may be given more frequently. A final infusion will be given at either week 42 or week 46. There will be a safety evaluation at week 54 and a visit at week 62 to get a blood sample. Patients will receive 5 mg/kg of infliximab at weeks 0, 2 and 6 and then 5mg/kg infliximab either every 8 weeks or 12 weeks until weeks 42 or 46. Infliximab is given as an intravenous infusion over 2 hours.
NVAF patients who taking rivaroxaban tablet 15mg，bid during 2016.2-2021.1，the duration of continuous medication was more than 3 months.PDC value and mmas-8 scale were used to evaluate the compliance of patients with dabigatran. PDC value and mmas-8 scale were used to evaluate the compliance of patients with rivaroxaban.
The aerobic exercise regimen will be standardized according to the American College of Sports Medicine recommendations: frequency of a minimum of 5 sessions per week, at a vigorous intensity \[\>60% of oxygen uptake reserve (VO2R)\], time of 20-25 minutes per exercise session. To determine the exercise heart rate intensity, the Karvonen formula for heart rate reserve will be used. The mode of exercise will be purposeful walking or jogging. The goal of the exercise is not training, but rather to keep the participant's heart rate \>60% of their individually-determined heart rate reserve.
Subjects will receive reinforcement for BG testing. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
The investigators propose to conduct 3 related randomized, controlled, parallel group, assessor-blind, superiority trials of 6-week text message interventions vs. SMS vehicle safety self-monitoring in young adult participants with risky vehicle behaviors. A total of 500 adult participants will be enrolled: 300 into Cohort 1 (seat belt); 100 into Cohort 2 (distracted driving); 100 into Cohort 3 (drink driving). Each SMS intervention will be designed to target a single risk behavior. The study is powered to show a difference of 15% in the percentage of subjects reporting seat belt use at week 8. Other cohort trials (i.e. distracted driving, drink driving) and outcomes will be exploratory.
Patients should be advised of the signs and symptoms of both MAC and tuberculosis, and should be instructed to consult their physicians if they develop new complaints consistent with either of these diseases. In addition, since MYCOBUTIN may rarely be associated with myositis and uveitis, patients should be advised to notify their physicians if they develop signs or symptoms suggesting either of these disorders.

Urine, feces, saliva, sputum, perspiration, tears, and skin may be colored brown-orange with rifabutin and some of its metabolites. Soft contact lenses may be permanently stained. Patients to be treated with MYCOBUTIN should be made aware of these possibilities.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes, after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

There is no reason to believe that MYCOBUTIN has any adverse effect on the ability to drive and/or use machines.
Patients receive a single intravenous dose of Indium-111-DOTA-Labetuzumab-IRDye800CW. At day 4 or 5 after antibody injection a SPECT/CT scan will be acquired. At day 6 or 7 standard of care cytoreductive surgery will be performed. This will be extended with the use of dual-modality imaging.
The invention relates to a three-layer essence with repairing and moisturizing effects, which comprises a bottom water phase layer, a middle oil phase layer and a top oil phase layer. The bottom water phase layer comprises the following components in parts by weight: 4-8 parts of 1, 2-pentanediol, 8-15 parts of a humectant, 0.1-1 part of a water-soluble antioxidant, 1-2 parts of a water-soluble skin conditioner and 50-60 parts of water. The middle oil phase layer comprises the following components in parts by weight: 5-10 parts of castor (Ricinus COMMUNIS) seed oil, 0.1-1 part of oil-soluble skin conditioner and 0.1-0.5 part of aromatic. The top oil phase layer comprises the following components in parts by weight: 5-10 parts of C15-19 alkane, 10-15 parts of C9-12 alkane and 0.01-0.1 part of oil-soluble antioxidant. The invention also relates to a preparation method of the three-layer essence. The invention also relates to application of the three layers of essence in skin moisturizing and repairing.
OBJECTIVE: Surgical airway management is one of the most effective techniques for safe airway management. Within the training programs relating to knowledge and skills required by otorhinolaryngologists, tracheostomy and postoperative management are important items that must be fully understood by airway surgeons. We performed a nationwide survey to identify problems within tracheostomy and postoperative management in Japan in order to establish practical and safe guidelines for surgical airway management.
METHODS: We conducted a questionnaire survey of the current status of tracheostomy and postoperative management at core institution of otorhinolaryngology training programs in Japan.
RESULTS: Responses were obtained from all 101 core training institutions in Japan. Tracheostomy was performed in the operating room at 61.4% of institutions and in the ICU at 26.7%. 89.1% of them performed surgical tracheostomy (ST) in all cases. Even in the remaining 10.9%, percutaneous dilatational tracheostomy (PDT) was performed in less than 10% of cases. The primary surgeon was an otorhinolaryngology resident at 89.1% of institutions. The method of securing the tube immediately after surgery was by securing it with an attached cord at 48.5% of institutions, by suturing to the skin at 25.7%, and using a Velcro band at 24.8%. The first tube change after tracheostomy was performed on the seventh postoperative day at 81.2% of institutions. 87.1% had more than one person performing the first tube change. The tracheostomy postoperative complications within the past year were as follows: tracheostomal granulation: 89.1%; subcutaneous and/or mediastinal emphysema: 62.4%; tube stenosis: 55.4%; accidental tube removal: 50.5%; incorrect tube insertion or misplacement: 15.8%; hemorrhage from tracheal foramen requiring hemostasis in the operating room: 14.9%; pneumothorax: 4.0%; tracheo-innominate arterial fistula: 2.0%; and tracheoesophageal fistula: 1.0%. The method for educating otorhinolaryngology residents about tracheostomy was on-the-job training at 98.0% of institutions.
CONCLUSIONS: For airway management in otorhinolaryngology training programs, after learning the basics of ST, PDT should also be well understood. Furthermore, in order to create safe educational programs for intraoperative and postoperative management, it is necessary to train otorhinolaryngologists with accurate knowledge and skills, and to strengthen collaboration with multiple professions in their leadership roles as airway surgeons.
In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
The invention discloses a conditioned medium which comprises the following components in parts by weight: 0-0.05 part of basic fibroblast growth factor, 0-0.05 part of epidermal growth factor, 94.9-95.9 parts of dulbecco modified eagle medium (DMEM)/ F12, 1 part of antibiotics, 1 part of glutamate, 1 part of non-essential amino acid and 0-1 part of antioxidant. The invention also discloses a cell-activating essence product and a preparation method of the cell-activating essence product. The invention further discloses the application of the cell-activating essence product. The used conditioned medium does not contain animal-based substances, so that the problems of irritability, infection and the like caused by the differences among species can be avoided.  Adipose-derived stem cells (ADSCs) are separated by stages by virtue of the mixed enzyme; and the yield of the ADSCs is 3000-5000/ mg. The conditioned medium is used for promoting secretion, so that the content of protein active factor can be increased and the treatment effect of the cell-activating essence product can be improved.
To provide a composition useful for inhibiting biofilm formation due to Enterococcus, cariogenic bacteria, or periodontal bacteria.SOLUTION: The present techniques include a composition for inhibiting biofilm formation due to Enterococcus, cariogenic bacteria, or periodontal bacteria, the composition containing lactoferrin or lactoferrin hydrolysate. Preferably, the composition contains heat-treated lactoferrin. The composition may be in the form of an aqueous solution. Specifically, the composition may be a heated product of lactoferrin-containing aqueous solution. The present techniques also provide a biocleaning aqueous solution that contains lactoferrin or lactoferrin hydrolysate. The biocleaning aqueous solution may contain heat-treated lactoferrin. The aqueous solution may be used to clean the intraoral cavity or a wound site.SELECTED DRAWING: None
Triosephosphate isomerase deficiency (TPI Df) is a devastating childhood degenerative disease for which there are currently no treatments.    Pathogenesis of this disease is driven by mutations that destabilize the TPI protein. A genome-wide RNAi screen in  Drosophila  to identify regulators of TPI stability is described. The screen identified 25 proteins that are critical to TPI stability, each of which has a human ortholog. Methods of promoting TPI protein stability and treating TPI Df in a subject by administering a therapeutically effective amount of an agent that inhibits expression or activity of one of the identified regulators are described. Also described is a method for the identification of agents capable of promoting stability of mutant TPI. Methods for treating a subject who has TPI Df by administering an agent that promotes stability of mutant TPI is also described.
Tree nuts are recommended in the prevention and management of cardiovascular disease (CVD) largely based on their LDL (low density lipoprotein) lowering effects, but the CVD risk reduction observed with tree nut consumption is greater than that predicted by their hypocholesterolemic effects alone. Other health benefits have also been noted by our group, such as moderation of postprandial lipemia , as well as by others such as modified postprandial glycemia , decreased blood pressure (BP) , improvement in oxidant status and weight loss. Robust evidence for the protective cardio-metabolic effects of nuts from the PREDIMED study has highlighted the association between nut consumption and decreased risk of cardiovascular events, obesity, metabolic syndrome and type 2 diabetes (T2DM). However, there is a paucity of evidence on the effects of almonds on vascular function in humans (BP and endothelium-dependent vasodilation (EDV)), although there is evidence that almonds promote nitric oxide (NO) release in animals consuming high-fat diets. Fundamental to vascular health is a well-functioning liver and there is increasing evidence to demonstrate that the accumulation of liver fat is a causative factor in the development of cardio-metabolic disorders. Non-alcoholic fatty liver disease (NAFLD) is now considered the hepatic manifestation of the metabolic syndrome (MetS); recent data has shown that it is linked to increased CVD risk via direct effects on vascular function (and EDV) independently of obesity and MetS . NAFLD is thought to affect 30% of the population in developed countries, and up to two-thirds of people with obesity and 50% of people with hyperlipidemia. Development of fatty liver, mainly attributable to obesity and elevated postprandial lipemia, is associated with increased inflammation, oxidative stress, insulin resistance, dyslipidemia and impaired EDV, and predicts risk of CVD and T2DM .

Therefore, the long-term goal of this research is to understand the mechanisms underpinning how dietary change can drive favourable modification of CVD disease risk and to identify patterns in population food choices, specifically almond consumption, that tend to correlate with reduced CVD disease risk. The primary aim of this proposal is to investigate, in a randomised controlled, parallel arm, 6-wk dietary intervention (n=100) whether replacing snacks based on refined carbohydrates and poor in micronutrients/non-nutrient bioactives (NNB) with nutrient/NNB-dense, whole almond snacks can influence liver fat content (a key metabolic driver of insulin resistance and vascular dysfunction, and a hallmark of metabolic syndrome) and EDV (brachial FMD being an independent predictor of CVD events, in addition to related biomarkers of cardio-metabolic disease risk. The snacks products provide participants with 20% of their energy requirements via either whole almonds or as muffins/crackers that have been designed to mimic the average UK snack.
Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 3 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
Systems and methods for medical intervention using machine learning techniques are provided. One or more embodiments include receiving data associated with a medical condition from a user. Based on the user, a patient profile is retrieved from a database. An intervention is determined for the medical condition based on a patient history provided as an input to a machine learning model that recommends interventions. The intervention is sent to a user device associated with the user. Changes are monitored in one or more health metrics associated with the user. The machine learning models are re-trained based on the monitored changes and the intervention.
The group A incorporates three subgroups of individuals at various ages. A.1 Age: 16 - 30 A.2 Age: 31 - 60 A.3 Age \> 60 All subgroups will be randomly distributed according to the following factors: BMI, gender, race and hematocrit.
PROBLEM TO BE SOLVED: To obtain the subject mold material convertible into a muddy form and capable of preparing a model and, in the process, eliminating the necessity for applying a separating agent onto a boundary surface not only with a wax pattern but also with an impression, etc., by using a silicone oil as a mold releasing agent of an anhydrite powder for dental use. SOLUTION: This mold material is obtained by adding and mixing (A) an anhydrite powder for dental use with (B) a silicone oil as a mold release agent in an amount of 0.01-1 wt.% based on the component A. The component B is a silicone oil good in mold releasability such as dimethyl silicone oil and preferably having about 0.8-1.2 specific gravity (at 25 deg.C). Furthermore, the ingredient B can be dissolved in an organic solvent for use. The mold material is capable of retaining a powdery state similar to that of a conventional anhydrite powder for the dental use. An adequate amount of water, e.g. that in an amount of 17-23 pts.wt. based on 100 pts.wt. of the powder can be added thereto to provide a muddy state, which can be molded into an optional shape and hardened to prepare a gypsum model.